Axium Healthcare Pharmacy Now Dispensing Epclusa®, the First Oral Medication FDA-Approved to Treat All Hepatitis C Genotypes

Share Article

Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotypes 2 and 3, without the need for ribavirin.

Axium Healthcare Pharmacy announced today that it is dispensing Gilead’s Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with chronic hepatitis C virus (HCV) infections, genotypes 1-6. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotypes 2 and 3, without the need for ribavirin. A 12-week regimen of Epclusa was approved in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C). Providers and patients can find full prescribing information at http://www.epclusainfo.com.

“Simpler all-oral dosing, shorter treatment durations, and high success rates across all hepatitis C genotypes—through a single medication—have created a promising milestone in today’s HCV therapy options,” commented Mark Montgomery, President and CEO of Axium Healthcare Pharmacy. “This is a particularly exciting development for patients with genotypes 2 and 3 who, until now, have had fewer, yet more complex treatment options to work with. Through medications like Epclusa, we are pleased to simplify the path to better outcomes for patients and providers.”

Axium dispenses and supports Epclusa therapy through its HepVisions® program. With HepVisions, patients and providers get:

  •     Clinical support for adherence, side effect management, appropriateness of therapy, and drug utilization review.
  •     Insurance Verification and Prior Authorization. Axium handles insurance verifications within 24 to 48 hours, and works with many third-party prescription plans.
  •     Copay assistance for qualifying patients.
  •     24 x 7x 365 clinical support.
  •     Convenient, confidential medication delivery.

In addition, providers can save time with Axium’s #oneteam single source referral program. The program means that Axium now accepts referrals for all hepatitis C specialty medication patients, and will perform—and complete—full prior authorization work, if permitted by health plans, even if it cannot fill the prescription.

Download Axium’s hepatitis C referral form from http://www.axiumhealthcare.com today.

About Axium Healthcare Pharmacy

Founded in 2000, Axium Healthcare Pharmacy, Inc. is a nationwide provider of specialty pharmacy services. A wholly-owned subsidiary of The Kroger Company, Axium provides drug therapies and patient support services to treat chronic, genetic, and other complex conditions such as Hepatitis C, Multiple Sclerosis, Cancer, Rheumatoid Arthritis, and a number of others.

For more information, contact Axium Healthcare Pharmacy at 888.315.3395 or visit http://www.axiumhealthcare.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Wendy Bacigalupi

Roxie Mooney
@AxiumHP
Follow >
Axium Healthcare Pharmacy
since: 01/2011
Like >
Follow us on
Visit website